Abstract:Pigment epithelium-derived factor (PEDF) was recently found to be closely associated with metabolic syndrome and insulin resistance. However, there is a lack of evidence quantitating PEDF levels in subjects with different glucose tolerance status and it is not known whether metformin treatment can affect PEDF concentrations. In this study, 517 Chinese subjects were categorized as having normal glucose tolerance (NGT), impaired glucose regulation (IGR), or type 2 diabetes mellitus (T2DM) using the guidelines of the International Diabetes Federation. In addition, 63 patients with newly diagnosed T2DM were treated for 24 weeks with metformin. Circulating PEDF concentrations and metabolic profiles were assessed. The study protocol was approved by the Ethics Committee of Drum Tower Hospital. Body mass index (BMI) classifications were in accordance with World Health Organization guidelines. Of the 517 participants (42.6% men, 57.4% women; mean [± SD] age 49.7 ± 14.5 years), 186 had NGT, 216 had IGR, and 169 had diabetes. Median serum PEDF concentrations were significantly higher in subjects with IGR (9.5 μg/mL; interquartile range [IQR] 7.6–11.4 μg/ mL) and T2DM (9.7 μg/mL; IQR 7.9–11.7 μg/mL), than in those with NGT (8.5 μg/mL; IQR 7.1–10.7 μg/mL; P = 0.010; Fig. 1a). For the metformin-treated group, PEDF concentrations were significantly lower after treatment in T2DM patients who lost weight (n = 47; from 9.2 [7.2–11.7] to 8.1 [6.2–9.9] μg/mL; P = 0.027), whereas there was no significant difference in PEDF concentrations before and after metformin treatment in the group of patients who did not lose weight on metformin treatment (n = 16; 9.1 [7.8–11.1] vs 10.6 [7.1–13.0] μg/mL, respectively; P > 0.05; Fig. 1b). Spearman correlation analysis demonstrated that PEDF concentrations were significantly correlated with risk factors for metabolic syndrome and visceral obesity (P < 0.001). In multiple stepwise regression, PEDF was associated with alanine aminotransferase (P < 0.001), triglycerides (P = 0.002) and diastolic blood pressure (P = 0.002) after adjustment for age and gender. Subjects in the second and third tertiles of PEDF concentrations (8.0–10.4 and 10.4–32.0 μg/mL, respectively) exhibited a higher prevalence of overweight or obesity than those in the first tertile (3.2–8.0 μg/mL; P < 0.001), and the prevalence of overweight or obesity was higher for those in the third tertile than in the second tertile. Furthermore, serum PEDF concentrations were significantly higher in men than in women (9.6 [7.9–11.9] vs 8.9 [7.4–10.8] μg/mL, respectively; P = 0.003) and this difference remained after adjusting for BMI, waist circumference, and the waist-to-hip ratio (P = 0.009; Fig. 1c). Estradiol concentrations were negatively associated with PEDF (r = −0.216, P = 0.013; Fig. 1d) and were independent determinants of PEDF in postmenopausal women. In conclusion, PEDF concentrations are significantly elevated in patients with glucose intolerance and could be reduced by metformin treatment in T2DM patients who lost weight while on metformin treatment. Some in vitro studies have suggested a link between estradiol and PEDF concentrations. To the best of our knowledge, the present study is the first to identify decreased estradiol as an independent risk factor for increased PEDF concentrations, which may contribute to the occurrence of T2DM in postmenopausal women.

The relations between serum pigment epithelium-derived factor and insulin resistance in type 2 diabetes

Serum Level of Pigment Epithelium-Derived Factor in Different Glucose Tolerance State

[Change and Significance of Serum Pigment Epithelium-Derived Factor in Type 2 Diabetic Nephropathy].

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes

Elevated Plasma Concentrations of Pigment Epithelium‐derived Factor in Type 2 Diabetic Patients is Reduced by Metformin Treatment in Association with Weight Loss

Relationship between Plasma Phospholipid Fatty Acid Profile and Insulin Resistance in Type 2 Diabetics

[Effects of Insulin on Pigment Epithelium-Derived Factor Expression in Adipocytes of Type 2 Diabetic Mellitus in Rats].

Relation of Serum Ferritin with Type 2 Diabetes Mellitus and Its Relative Risk Factors

PEDF Expression is Inhibited by Insulin Treatment in Adipose Tissue Via Suppressing 11Β-Hsd1.

Serum Irisin Level and Its Correlation with Insulin Resistance in Patients with Type 2 Diabetes

Study on the Relations Between Abnormality of Insulin Resistance, Serum Leptin and Fatty Liver in Type 2 Diabetes Mellitus

[Selenoprotein P in Type 2 Diabetes Mellitus and Its Association with Insulin Resistance].

Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease

Relationship between type 2 diabetes mellitus and serum stromal cell derived factor 1 levels

Change of Retinol Binding Protein-4 Concentrations in Patients with Type 2 Diabetes Mellitus and Its Relationship with Glucose and Lipid Metabolism

The Correlation Between the Degree of Fat Deposition in the Pancreas and Insulin Resistance in Newly Diagnosed Type 2 Diabetes Mellitus Patients

Serum N-3 Polyunsaturated Fatty Acid and High-sensitivity C Reactive Protein in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Influence of circulating nesfatin-1, GSH and SOD on insulin secretion in the development of T2DM

Correlation of serum sex hormone binding globulin and type 2 diabetes mellitus

Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy in Egyptian patients with type 2 diabetes mellitus